Sutro Biopharma, Inc. STRO
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2018 · data as of November 13, 2026
Sutro Biopharma, Inc. (STRO) is a healthcare company listed in the US with a market value of about $163M. In the twelve months to September 30, 2026 it had revenue of $45M and net income of -$155M, a net margin of -344.2%.
Its overall Stock Analiz score is 1.4 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 19% a year, a 5-year average ROIC of -97%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 97% below the current price.
About Sutro Biopharma
Sutro Biopharma is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2018. Revenue went from $60M in 2016 to $102M in 2025, growth of about 6.2% a year. It was profitable in 1 of the last 10 years in our data. Its share count rose by 66% over three years (dilution for shareholders). It spends 162% of revenue on research and development.
Score: 1.4 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- ROE above 15%
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $45M | $102M | $62M | $154M | $68M | $62M | $43M | $43M | $38M | $52M | $60M |
| Net income | -$155M | -$191M | -$227M | -$107M | -$119M | -$106M | -$32M | -$119M | -$35M | -$20M | $2M |
| Free cash flow | — | — | — | — | — | — | — | — | $11M | -$40M | -$18M |
| EPS (diluted) | $-12.63 | $-22.49 | $-29.40 | $-17.68 | $-23.34 | $-22.74 | $-9.83 | $-24.13 | $-60.87 | $-436.44 | $0.00 |
| Net margin | -344.2% | -186.5% | -366.6% | -69.5% | -175.9% | -170.6% | -75.2% | -278.9% | -91.9% | -38.0% | 2.9% |
| ROIC | — | — | -278.0% | -38.5% | -38.1% | -31.8% | -14.5% | -40.7% | -20.1% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 13 analysts is $44.62, 354% above the current price; targets range from $10.00 to $61.00; the consensus rating is “Strong buy”; expected EPS is $-6.22 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Sutro Biopharma stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 97% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Sutro Biopharma pay a dividend?
Not currently.
Is Sutro Biopharma a good stock to buy?
We do not give buy or sell advice. Sutro Biopharma scores 1.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.